Скачать или смотреть The CETP-Inhibitor Obicetrapib in FH: BROOKLYN - Prof. Dr. Stephen Nicholls (Melbourne, Australia)

Prof. Dr. Stephen Nicholls presents data from the phase 3 BROOKLYN study, which has evaluated the effects of obicetrapib in patients with heterozygous familial hypercholesterolemia on top of maximum tolerated lipid-modifying therapies.

Prof. Nicholls is Director of Victorian Heart Hospital, MonashHeart and Intensive Care, and Director of Victorian Heart Institute in Melbourne, Australia. As a world leader in clinical and academic lipology, Prof. Nicholls has been principal investigator of landmark studies in cardiology and lipidology.

The interview was recorded on January 14th, 2025.

Moderators: Prof. Dr. Florian Custodis (Saarbrücken, Germany), Prof. Dr. Dr. Stephan Schirmer (Kaiserslautern, Germany) and Prof. Dr. Gunnar Heine (Frankfurt, Germany).

Articles discussed:

Increasing HDL Cholesterol Levels.
Brewer HB Jr.
N Engl J Med 2004
doi: 10.1056/NEJMp048023

Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, Zinman B, Zoungas S, Basile J, Bartee A, Miller D, Nishiyama H, Pavo I, Weerakkody G, Wiese RJ, D'Alessio D; SURPASS-CVOT investigators.
Am Heart J 2024
doi: 10.1016/j.ahj.2023.09.007

Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels.
Nelson AJ, Sniderman AD, Ditmarsch M, Dicklin MR, Nicholls SJ, Davidson MH, Kastelein JJP.
Int J Mol Sci 2022
doi: 10.3390/ijms23169417

Effects of torcetrapib in patients at high risk for coronary events.
Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators.
N Engl J Med 2007
doi: 10.1056/NEJMoa0706628

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin M, Chang T, Hellawell J, Watts GF; ARCHES-2 Trial Team.
N Engl J Med 2024
doi: 10.1056/NEJMoa2404147

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D.
N Engl J Med 2024
doi: 10.1056/NEJMoa2404143

Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.
N Engl J Med 2012
doi: 10.1056/NEJMoa1206797

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators.
N Engl J Med 2017
doi: 10.1056/NEJMoa1609581

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
HPS3/TIMI55–REVEAL Collaborative Group; Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ.
N Engl J Med 2017
doi: 10.1056/NEJMoa1706444